MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

NRBO 12.19.2024

Full Press ReleaseSEC FilingsOur NRBO Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
  • 01.09.2025 - January 9, 2025 - January 11, 2025 : 9th Annual MASH-TAG 2025 Conference
  • 01.01.2025 - Ed Arce

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
  • 12.02.2024 - 4 Statement of changes in beneficial ownership of securities

CAMBRIDGE, Mass.,Dec. 19, 2024/PRNewswire/ --MetaVia Inc.(Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9thAnnual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).The MASH-TAG Conferenceis taking placeJanuary 9-11at theChateaux Deer ValleyinPark City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.

MetaVia Logo (PRNewsfoto/MetaVia Inc.)

About MetaViaMetaVia Inc.is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visitwww.metaviatx.com.

Contacts:

MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033marshall.woodworth@metaviatx.com

Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-the-9th-annual-mash-tag-2025-conference-after-releasing-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241-in-patients-with-presumed-mash-302335535.html

SOURCEMetaVia Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com